Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2
Go back to Merck Presents New Data from Ongoing Phase 2b Clinical Trial Evaluating Efficacy and Safety of Investigational Islatravir in Combination With Doravirine Through 144 Weeks for HIV-1 Treatment at EACS 2| Merck & Co. (NYSE: MRK) | Delayed: 149.50 +2.63 (1.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.87 | 52 Week High | $65.46 | |||
| Open | $146.79 | 52 Week Low | $47.97 | |||
| Day High | $150.49 | P/E | 101.70 | |||
| Day Low | $145.60 | EPS | $1.47 | |||
| Volume | 7,996,283 | |||||
